Zhu Yan, Liu Quanxi
Department of Gastroenterology, Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, 100039, China.
Iran J Public Health. 2025 Mar;54(3):478-488. doi: 10.18502/ijph.v54i3.18241.
We aimed to evaluate the effectiveness and safety of Shaoyao Tang in treating ulcerative colitis (UC) through a randomized controlled meta-analysis.
Computer searches were conducted between Jan 2000 and Mar 2023 using the databases of CNKI, VIP, PubMed, the Cochrane Library, Wanfang and Web of Science in search of trials with randomization and control including Shaoyao decoction in UC. After quality assessment, The Revman 5.3 was applied.
Overall, 23 articles were selected for the study totally. Shaoyao decoction improved clinical effective rate (<0.001) and effective rate of syndrome (<0.001), IBDQ (<0.001), interleukin-4 (<0.001) and interleukin-10 (<0.001), reduced adverse reactions (=0.004), recurrence rate (=0.03), DAI (<0.001), tumour necrosis component α (<0.001), interleukin-1β (<0.001), interleukin-6 (<0.001), and extremely sensitive C-reactive protein (=0.02).
Shaoyao decoction has certain advantages and good safety in the treatment of UC; however the findings still need to be supported by excellent studies.
我们旨在通过随机对照荟萃分析评估芍药汤治疗溃疡性结肠炎（UC）的有效性和安全性。
于2000年1月至2023年3月期间进行计算机检索，使用中国知网、维普、PubMed、考克兰图书馆、万方和Web of Science数据库，以查找有关UC中包含芍药汤的随机对照试验。经过质量评估后，应用Revman 5.3软件。
总体而言，共选择23篇文章进行研究。芍药汤提高了临床有效率（<0.001）、证候有效率（<0.001）、炎症性肠病问卷（IBDQ）评分（<0.001）、白细胞介素-4（<0.001）和白细胞介素-10（<0.001），降低了不良反应发生率（=0.004）、复发率（=0.03）、疾病活动指数（DAI）（<0.001）、肿瘤坏死因子α（<0.001）、白细胞介素-1β（<0.001）、白细胞介素-6（<0.001）以及超敏C反应蛋白（=0.02）。
芍药汤在UC治疗中具有一定优势且安全性良好；然而，这些研究结果仍需高质量研究的支持。
